Handelsbanken Fonder Ab Allakos Inc. Transaction History

Handelsbanken Fonder Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$8.55 - $111.89 $473,670 - $6.2 Million	-55,400 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$76.53 - $110.43 $6.51 Million - $9.39 Million	-85,000 Reduced 60.54%	55,400 $5.87 Million
Q2 2021 Aug 03, 2021	SELL	$85.37 - $114.1 $42,685 - $57,050	-500 Reduced 0.35%	140,400 $12 Million
Q1 2021 Apr 29, 2021	BUY	$109.73 - $153.66 $351,136 - $491,712	3,200 Added 2.32%	140,900 $16.2 Million
Q2 2020 Aug 13, 2020	SELL	$44.04 - $80.69 $13,212 - $24,207	-300 Reduced 0.22%	137,700 $9.9 Million
Q1 2020 May 14, 2020	BUY	$44.49 - $93.39 $3.03 Million - $6.35 Million	68,000 Added 97.14%	138,000 $6.14 Million
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $4.65 Million - $9.64 Million	70,000 New	70,000 $6.68 Million

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $25.4M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.